New funder signs on for Mesoblast shareholder class action
Class Actions 2022-02-18 10:58 amBy Cat Fredenburgh | Melbourne
Please login to bookmark Close

A new funder is backing a shareholder class action that will be brought against Australian regenerative medicine company Mesoblast over disclosures related to its Remestemcel-L treatment for COVID-19 complications.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au